Dartmouth Cancer Center Appoints Dr. Roy S. Herbst as New Director
達特茅斯癌症中心任命羅伊·S·赫布斯特博士為新任主任
The Dartmouth Cancer Center (DCC) has announced a significant leadership transition.
達特茅斯癌症中心（DCC）宣布了一項重大的人事異動。
Roy S.
Herbst博士為其第六任主任，其任期於2026年7月13日正式開始。
Herbst as its sixth director, with his tenure officially beginning on July 13, 2026.
Herbst博士從耶魯癌症中心加入該機構，他在該中心曾是腫瘤內科與藥理學領域的傑出領導者。
Herbst joins the institution from the Yale Cancer Center, where he was a prominent leader in medical oncology and pharmacology.
他因領導「BATTLE」與「Lung-MAP」等創新臨床試驗而廣受認可，這些試驗幫助改變了研究人員將標靶治療與特定病患生物標記進行配對的方式。
Herbst is celebrated for his groundbreaking work in precision medicine and immunotherapy, particularly regarding lung cancer.
他的首要目標包括擴大臨床試驗的參與管道，並強化新英格蘭地區的癌症照護，特別著重於服務偏鄉人口。
He is widely recognized for leading innovative clinical trials like 'BATTLE' and 'Lung-MAP,' which helped transform how researchers match targeted therapies to specific patient biomarkers.
DCC是一所享有盛譽、獲國家癌症研究所（NCI）指定的綜合性中心，也是該地區唯一座落於主要都會中心之外的同類機構。
His primary goals include expanding access to advanced clinical trials and strengthening cancer care across New England, with a special focus on serving rural populations.
The DCC is a prestigious National Cancer Institute-designated comprehensive center and the only one of its kind in the region located outside a major urban hub.
